Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage

Clinics and Research in Hepatology and Gastroenterology

Volumn 40, Issue 4, 2016, Pages 397-404

  Lin, Ling ^a,b   Lu, Baochun ^a,b   Yu, Jianhua ^a,b   Liu, Wenguang ^c   Zhou, Aijin ^c  

^a SHAOXING PEOPLE S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; MICRORNA; MICRORNA 224; UNCLASSIFIED DRUG; MIRN224 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CHRONIC HEPATITIS B; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; EARLY CANCER DIAGNOSIS; LIVER TUMOR; REAL TIME POLYMERASE CHAIN REACTION;

ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84951790933     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.11.005     Document Type: Article

References (35)

1. [1] Bosch, F.X., Ribes, J., Diaz, M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (2004), S5–S16.
2. [2] Yuen, M.F., Hou, J.L., Chutaputti, A., et al. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 24 (2009), 346–353.
3. [3] Srivatanakul, P., Sriplung, H., Deerasamee, S., Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 5 (2004), 118–125.
4. [4] Schwartz, M., Roayaie, S., Konstadoulakis, M., Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4 (2007), 424–432.
5. [5] Kim do, Y., Kim, J.W., Kuromatsu, R., et al. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology 81:Suppl. 1 (2011), 56–60.
6. [6] Terentiev, A.A., Moldogazieva, N.T., Alpha-fetoprotein: a renaissance. Tumour Biol 34 (2013), 2075–2091.
7. [7] Llovet, J.M., Villanueva, A., Lachenmayer, A., et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol, 12, 2015, 436.
8. [8] Schwarzenbach, H., Nishida, N., Calin, G.A., et al. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11 (2014), 145–156.
9. [9] Giordano, S., Columbano, A., MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?. Hepatology 57 (2013), 840–847.
10. [10] Shen, J., Stass, S.A., Jiang, F., MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 329 (2013), 125–136.
11. [11] Papaconstantinou, I., Karakatsanis, A., Gazouli, M., et al. The role of microRNAs in liver cancer. Eur J Gastroenterol Hepatol 24 (2012), 223–228.
12. [12] Wang, Y., Lee, C.G., Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?. Epigenomics 3 (2011), 235–243.
13. [13] Wang, Y., Lee, A.T., Ma, J.Z., et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 283 (2008), 13205–13215.
14. [14] Li, Q., Wang, G., Shan, J.L., et al. MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol 25 (2010), 164–171.
15. [15] Zhang, Y., Takahashi, S., Tasaka, A., et al. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol 28 (2013), 565–575.
16. [16] Gao, P., Wong, C.C., Tung, E.K., et al. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 54 (2011), 1177–1184.
17. [17] Ladeiro, Y., Couchy, G., Balabaud, C., et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47 (2008), 1955–1963.
18. [18] Pineau, P., Volinia, S., McJunkin, K., et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107 (2010), 264–269.
19. [19] Scisciani, C., Vossio, S., Guerrieri, F., et al. Transcriptional regulation of miR-224 upregulated in human HCCs by NFkappaB inflammatory pathways. J Hepatol 56 (2012), 855–861.
20. [20] Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma. Lancet 379 (2012), 1245–1255.
21. [21] Forner, A., Reig, M.E., de Lope, C.R., et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30 (2010), 61–74.
22. [22] Mitchell, P.S., Parkin, R.K., Kroh, E.M., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105 (2008), 10513–10518.
23. [23] Schmittgen, T.D., Livak, K.J., Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3 (2008), 1101–1108.
24. [24] Cortez, M.A., Bueso-Ramos, C., Ferdin, J., et al. MicroRNAs in body fluids – the mix of hormones and biomarkers. Nat Rev Clin Oncol 8 (2011), 467–477.
25. [25] Witjes, C.D., van Aalten, S.M., Steyerberg, E.W., et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int 7 (2013), 59–64.
26. [26] Gui, J., Tian, Y., Wen, X., et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond) 120 (2011), 183–193.
27. [27] Li, J., Wang, Y., Yu, W., et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 406 (2011), 70–73.
28. [28] Marrero, J.A., Feng, Z., Wang, Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137 (2009), 110–118.
29. [29] Li, L.M., Hu, Z.B., Zhou, Z.X., et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70 (2010), 9798–9807.
30. [30] Qu, K.Z., Zhang, K., Li, H., et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 45 (2011), 355–360.
31. [31] Xu, J., Wu, C., Che, X., et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50 (2011), 136–142.
32. [32] Zhou, J., Yu, L., Gao, X., et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 29 (2011), 4781–4788.
33. [33] Liu, A.M., Yao, T.J., Wang, W., et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open, 2, 2012, e000825.
34. [34] Wen, Y., Han, J., Chen, J., et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer 137 (2015), 1679–1690.
35. [35] Huang, J.T., Liu, S.M., Ma, H., et al. Systematic review and meta-analysis: circulating miRNAs for diagnosis of hepatocellular carcinoma. J Cell Physiol 231 (2015), 328–335.